Botulinum Toxin Type A: What Differs Between Products

Anyone who works with botulinum toxin hears the same question every week: "which one is the best?". Patients often use a brand name as a synonym for the active ingredient and assume all vials are the same, or that one is always "stronger". In practice, type A toxin products share the active ingredient but are not identical, and the differences matter for planning, stock and documentation.

This guide explains, at a review level and without naming brands, what changes between products. It does not give doses, dilutions or injection points. The basis of clinical reasoning (mechanism, dynamic and static wrinkles, muscle balance) is in botulinum toxin in HOF: fundamentals.

What do all the products have in common?

Products used in facial aesthetics contain botulinum neurotoxin serotype A, a protein that temporarily blocks acetylcholine release at the neuromuscular junction. That molecule, the neurotoxin itself, produces the clinical effect. So all of them have a broadly similar mechanism of action, gradual onset and temporary effect.

In Brazil, botulinum toxin is a biologic drug, registered with ANVISA, with an approved label and sold by prescription. Each registered product has its own approved indications, listed on the label.

So what actually differs between one product and another?

The table describes categories of difference. The values for each product (temperature range, time after reconstitution, units per vial, excipients) are in the current label and change with updates. Always check the current version.

What are complexing proteins?

In nature, the neurotoxin is produced by the bacterium together with other proteins that bind to it and form a larger complex. These accompanying proteins are called complexing proteins, and they have no effect of their own on the neuromuscular junction.

Industrial processes handle this differently: some products keep the neurotoxin inside the complex, while others purify the neurotoxin and remove the accompanying proteins. Once in the tissue, the neurotoxin separates from the complex to act.

Two points usually come up in the discussion:

• Immunogenicity: the formation of neutralizing antibodies, which can reduce the response to the toxin, is considered rare. It is generally associated with high cumulative doses and short intervals between treatments. Whether the total protein load, including complexing proteins, influences this risk is discussed; the topic is not settled.
• Diffusion: the idea that one product "spreads more" than another because of complex size is debated. Injected volume, dose, concentration and technique weigh heavily on diffusion, whatever the product.

Why are units not interchangeable?

The toxin unit measures biological activity, and each manufacturer defines it with its own potency assay. Labels state that the units of one product are not interchangeable with those of others, as the glossary entry toxin unit explains.

The literature includes ratios between products, but none is an official conversion, and the studies themselves disagree. In practice:

• a dose without the product name means nothing;
• switching products requires reviewing the planning based on the label, not multiplying by a factor;
• dilution volume changes concentration, not the dose in units;
• the patient record should document product, lot, expiry, dilution and units per area.

Does storage change from one product to another?

It does. Some products have labels requiring the closed vial to be refrigerated, and others are described as stable at room temperature before reconstitution, within a defined range. Once reconstituted, each product has its own shelf life and storage condition.

For the practice, this means:

1. Separate the routine by product: if you work with more than one, each follows its own label.
2. Monitor the refrigerator temperature when required, with a log, and do not store the vial in the door.
3. Write the date and time of reconstitution on the vial and respect the label's use-by window.
4. Dispose of it following the health rules on the service's waste.

Storage failures are a possible cause of a below-expected response and do not show up on the label. That is why control must be documented.

Is there a toxin that lasts longer?

There is no single answer. Onset and duration of effect depend on dose, muscle, muscle strength, product and each patient's metabolism. Comparisons between products depend on the doses compared, and a higher dose of one product may last longer than a lower dose of another without saying anything about the product itself.

With the patient, talk in ranges and say "in general", never promise a duration.

How do I check ANVISA registration?

The registration of any product can be checked on the ANVISA search portal, through the drug search, using the product name or active ingredient. It is worth confirming:

• that the registration is valid;
• that the holder company is the one shown on the packaging;
• which indications appear on the approved label;
• the most recent label, for storage and reconstitution.

How should I choose the product for the practice?

The choice belongs to the qualified professional, following the rules of their professional board. Criteria that usually enter the decision:

Many professionals prefer to work with a few products, to build response experience and simplify documentation. Switching products without a clinical reason usually adds more variables than benefit.

How do I explain the difference to the patient?

The patient wants to know whether you use "the good one". The honest answer is that registered products share the same active ingredient and that the result depends far more on assessment, planning and dose than on the name on the vial.

Also record the product in the informed consent. For planning by area, see the glabella, the forehead lines and the eyebrow.

And in Harmy?

Harmy's Glabella point is linked to toxin in the glabella. In the Plan, the value for that area is a reference for the simulation, not the dose in units or the product: that information stays in your patient record. The projection shows the area smoother at rest, without distinguishing the product.

Toxin product checklist

1. Valid registration checked on ANVISA and the current label at hand.
2. Indication confirmed on the approved label.
3. Storage per the label, with temperature monitoring when required.
4. Date and time of reconstitution written on the vial.
5. Product, lot, expiry, dilution and units recorded in the patient record.
6. Product history and response asked about in the medical history.
7. No unit conversion between products.
8. Regulated supplier, with the invoice kept.